/Edwards%20Lifesciences%20Corp%20logo%20on%20phone-%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
Edwards Lifesciences has outperformed the S&P 500 recently, and analysts remain moderately optimistic about the stock’s prospects.
At the close of Heart Month, Edwards Lifesciences (NYSE: EW) underscored its leadership in structural heart innovation, advancing care through deep expertise and strong partnerships so people with structural...
Edwards Lifesciences Corporation (NYSE: EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences: Tuesday, March 10, 2026...
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in Citi’s Unplugged Medtech and Life Sciences Access Day on February 26, 2026. Scott Ullem, chief financial...
With after-tax profits surging by close to 50% year-over-year, AstraZeneca emerges as a potential winner among healthcare names reporting earnings this month.
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook ...
While Edwards Lifesciences has underperformed the S&P 500 over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2025 after the market closes on Tuesday, February 10, and will host a conference call at 5:00...
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 46 th Annual Health Care Conference on Monday, Mar. 2, 2026. Scott Ullem,...
Healthcare stocks rebounded in 2025. These three healthcare growth stocks offer exposure to innovation beyond traditional biotech risk